Key Highlights
- Charles River and Captain T Cell sign agreement for plasmid DNA and retrovirus vector production.
- Captain T Cell aims to develop TCR-T cell therapy for solid tumor patients.
- Program part of Charles River’s Cell and Gene Therapy Accelerator Program (CAP).
- Collaboration enhances access to CDMO capabilities and advisory services.
Source: Business Wire
Notable Quotes
- “We are thrilled to work with the Captain T Cell team to support the manufacture of its TCR-T cell cancer immunotherapy. Charles River has decades of success reliably manufacturing plasmid DNA, viral vectors, and cell therapies, helping to safeguard our customer programs and bring potential therapies to patients with limited options.” — Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing at Charles River
- “Captain T Cell is devoted to developing a new generation of toolbox-engineered T cell-based immunotherapies for solid tumor patients. We have the utmost confidence in the expertise of Charles River as we work to bring our lead candidate to the clinic.” — Felix Lorenz, CEO at Captain T Cell
SoHC's Take
The partnership between Charles River Laboratories and Captain T Cell represents a significant advancement in the field of cell and gene therapy, particularly for patients with solid tumors who have limited treatment options. Charles River’s extensive experience and established capabilities in plasmid and viral vector production will be instrumental in accelerating the development of Captain T Cell’s innovative TCR-T cell therapies. This collaboration not only underscores the potential of next-generation immunotherapies but also highlights the importance of strategic alliances in overcoming the complex challenges of bringing advanced therapies to clinical trials and, ultimately, to the patients who need them most.
